VTYX VENTYX BIOSCIENCES INC

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.

  • Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference

    Location: Virtual

    Date: Wednesday, February 12, 2025

    Time: 2:40-3:10 PM ET

A webcast of the presentation will be available in the Investors and News section of the Ventyx website at . A webcast replay will also be available on this website shortly after conclusion of the event for ninety days.

About Ventyx Biosciences

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.

Investor Relations Contact:

Joyce Allaire

Managing Director

LifeSci Advisors



EN
05/02/2025

Underlying

VTYXVENTYX BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VENTYX BIOSCIENCES INC

 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Hi...

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (G...

May 8, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Promine...

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment ...

April 1, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial...

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2VTX3232 in participants with obesity and cardiometabolic risk factors in H2VTX3232 biomarker study in patients with early Parkinson’s disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx ...

February 27, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Tri...

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025 Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on...

February 18, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healt...

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualD...

February 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch